Oragenics Inc (OGEN) Stock Price & Analysis
Oragenics Inc (OGEN) rose 0.00% to USD 0.51 as of July 25, 2026 at 03:09 UTC, according to Nexqual real-time market data.
OGEN last closed at USD 0.51; the session ranged USD 0.51–0.54 on volume of 12,865 shares. Market capitalization is —, with a 52-week range of USD 0.5–1.46 (ASE). Source: Nexqual, July 25, 2026 at 03:09 UTC.
Key Statistics (as of July 25, 2026 at 03:09 UTC)
| Price | USD 0.51 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.51 |
| Open | USD 0.51 |
| Day Range | USD 0.51 – 0.54 |
| 52-Week Range | USD 0.5 – 1.46 |
| Volume | 12,865 shares |
| Market Cap | — |
| Exchange | ASE |
Technical Analysis (OGEN)
Nexqual's technical model rates OGEN "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.53 (neutral) |
| vs SMA50 | Below (USD 0.58) |
| MACD | -0.02 (negative) |
From Oragenics Inc's Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- The first developer to receive FDA marketing approval for an orphan drug is entitled to a seven-year exclusive marketing period in the U.S. for the orphan drug indication.
- Interim patent extensions are not available for a drug for which an NDA has not been submitted.   Section 505(b)(2) New Drug Applications   Most drug products obtain FDA marketing approval pursuant to an NDA or an ANDA.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JAGX | Jaguar Health, Inc. | USD 0.96 | ▼ 27.59% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 9.88 | ▼ 6.7% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| IGC | IGC Pharma, Inc. | USD 0.26 | ▼ 2.22% |
| IBIO | iBio, Inc. | USD 1.43 | ▲ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:09 UTC. This page is informational and not investment advice.